Host factors in the pathogenesis of HIV disease

Immunological Reviews

Volumn 159, Issue , 1997, Pages 31-48

  Cohen, Oren J ^a   Kinter, Audrey ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR; CYTOKINE; NEUTRALIZING ANTIBODY; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENETIC POLYMORPHISM; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOGENETICS; LYMPHOID TISSUE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0030726383     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01005.x     Document Type: Review

References (264)

1. Fauci A. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-534.
2. Liu S-L, et al. Divergent patterns of progression to AIDS after infection from the same source: Human immunodeficiency virus type 1 evolution and antiviral responses. J Virol 1997;71:4284-4295.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
4. Wei X, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
6. Perelson AS, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-191.
7. Piatak M, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754.
8. Pantaleo G, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
9. Embretson J, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362.
10. Deng H, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
11. Dragic T, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
12. Alkhatib G, et al. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
13. Choe H, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1138.
14. Doranz B, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
15. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane domain, G-protein coupled receptor. Science 1996;272:872-877.
16. Berson J, Long D, Doranz B, Rucker J, Jirik F, Doms R. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996;70:6288-6295.
17. Liao F, Alkhatib G, Peden K, Sharma G, Berger E, Farber J. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both microphage-tropic and T cell line-tropic HIV-1. J Exp Med 1997;185:2015-2023.
18. Deng H, Unutmaz D, KewalRamani V, Littman D. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997;388:296-300.
19. Glauser M. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs 1996;52 (Suppl 2):9-17.
20. Bone R. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:690-691.
21. Paul W, Seder R. Lymphocyte responses and cytokines. Cell 1994;76:241-251.
22. Alonso K, Pontiggia P, Medenica R, Rizzo S. Cytokine patterns in adults with AIDS. Immunol Invest 1997;26:341-350.
23. Miedema F. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic Rev 1992;3:173-193.
24. Poli G, Fauci A. Role of cytokines in the pathogenesis of human immunodeficiency virus infection. In: Aggarwal B, Puri R, eds. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science; 1995. p. 421-449.
25. Lau A, Der S, Read S, Williams B. Regulation of tumor necrosis factor receptor expression by acid-labile interferon-α from AIDS sera. AIDS Res Hum Retroviruses 1991;7: 545-552.
26. Roux-Lombard P, Modoux C, Cruchaud A, Dayer J. Purified blood monocytes from HIV-1 infected patients produce high levels of TNF-α and IL-1. Clin Immunol Immunopathol 1989;50: 374-384.
27. Hober D, Haque A, Wattre P, Beaucaire G, Mouton Y, Capron A. Production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNF-alpha is related to a higher cytotoxic activity. Clin Exp Immunol 1989;78:329-333.
28. Voth R, et al. Differential gene expression of IFN-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS. J Immunol 1990;144:970-975.
29. Vyakarnam A, et al. Altered production of tumour necrosis factors alpha and beta and interferon gamma by HIV-infected individuals. Clin Exp Immunol 1991;84:109-115.
30. Weiss L, Haeffner-Cavaillon N, Laude M, Gilquin J, Kazatchkine MD. HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro. AIDS 1989;3:695-699.
31. Millar A, Miller R, Foley N, Meager A, Semple S, Rook G. Production of tumor necrosis factor-alpha by blood and lung mononuclear phagocytes from patients with human immunodeficiency virus-related lung disease. Am J Respir Cell Mol Biol 1991;5:144-148.
32. Krishnan V, Meager A, Mitchell D, Pinching A. Alveolar macrophages in AIDS patients: increased spontaneous tumor necrosis factor alpha production in Pneumocystis carinii pneumonia. Clin Exp Immunol 1990;80:156-160.
33. Antinori A, et al. Alveolar macrophages from AIDS patients spontaneously produce elevated levels of TNF-alpha in vitro. Allergol Immunopathol 1992;20:249-254.
34. Israel-Biet D, Cadranel J, Beldjord K, Andrieu J, Jeffrey A, Even P. Tumor necrosis factor production in HIV-seropositive subjects: relationship with lung opportunistic infections and HIV expression in alveolar macrophages. J Immunol 1991;147:490-494.
35. Reddy M, Sorrell S, Lange M, Grieco M. Tumor necrosis factor and HIV p24 antigen levels in serum of HIV-infected populations. J Acquir Immune Defic Syndr 1988;1: 436-440.
36. Lahdevirta J, Maury C, Teppo A, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-291.
37. Arditi M, Kabat W, Yogev R. Serum tumor necrosis factor alpha, interleukin 1-beta, p24 antigen concentrations and CD4+ cells at various stages of human immunodeficiency virus 1 infection in children. Pediatr Infect Dis 1991;10:450-455.
38. Scott-Algara D, Vuillier F, Marascescu M, deSaintMartin J, Dighiero G. Serum levels of IL-2, IL-1 alpha, TNF-alpha, and soluble receptor of IL-2 in HIV-1-infected patients. AIDS Res Hum Retroviruses 1991;7: 381-386.
39. Breen EC, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-484.
40. Rautonen J, Rautonen N, Martin NL, Philip R, Wara DW. Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS 1991;5:1319-1325.
41. Grimaldi LM, et al. Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol 1991;29:21-25.
42. Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol 1989;23:109-116.
43. Laurenzi MA, Siden A, Persson MA, Norkrans G, Hagberg L, Chiodi F. Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and non-inflammatory disease of the nervous system. Clin Immunol Immunopathol 1990;57: 233-241.
44. Kotler DP, Reka S, Clayton F. Intestinal mucosal inflammation associated with human immunodeficiency infection. Dig Dis Sci 1993;38:1119-1127.
45. Emilie D, et al. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest 1990;86:148-159.
46. Boyle MJ, et al. Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients. Clin Exp Immunol 1993;92:100-105.
47. Graziosi C, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994;265:248-252.
48. Wesselingh S, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993;33:576-582.
49. Dreno B, Milpied B, Dutartre H, Litoux P. Epidermal interleukin 1 in normal skin of patients with HIV infection. Br J Dermatol 1990;123:487-492.
50. Graziosi C, et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1996;93:4386-4391.
51. Fox C, Tenner-Rácz K, Rácz P, Firpo A, Pizzo P, Fauci A. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 1991;164:1051-1057.
52. Pantaleo G, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:9838-9842.
53. Jassoy C, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens. J Virol 1993;67:2844-2852.
54. Esser R, et al. Secretory repertoire of HIV-infected human monocytes/macrophages. Pathobiology 1991;59:219-222.
55. Clouse KA, Robbins PB, Fernie B, Ostrove JM, Fauci AS. Viral antigen stimulation of the production of human monokines capable of regulating HIV-1 expression. J Immunol 1989;143:470-475.
56. Molina J, Scadden D, Byrn R, Dinarello C, Groopman J. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989;84:733-737.
57. Rieckmann P, Poli G, Fox C, Kehrl J, Fauci A. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol 1991;147:2922-2927.
58. Merrill J, Koyanagi Y, Chen I. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989;63:4404-4408.
59. Brady H, Abraham D, Pennington D, Miles C, Jenkins S, Dzierzak E. Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J Virol 1995;69:7622-7629.
60. Hofman F, Wright A, Dohadwala M, Wong-Staal F, Walker S. Exogenous tat protein activates human endothelial cells. Blood 1993;82:2774-2780.
61. Blazevic V, Heino M, Lagerstedt A, Ranki A, Krohn K. Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV-1 infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:208-214.
62. Tyring S, et al. Synthetic peptides corresponding to sequences in HIV envelope gp41 and gp120 enhance in vitro production of interleukin-1 and tumor necrosis factor but depress production of interferon-alpha, interferon-gamma and interleukin-2. Viral Immunol 1991;4:33-42.
63. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79-84.
64. Schulick RD, Clerici M, Dolan MJ, Shearer GM. Limiting dilution analysis of interleukin-2-producing T cells responsive to recall and alloantigens in human immunodeficiency virus-infected and uninfected individuals. Eur J Immunol 1993;23:412-417.
65. Clerici M, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-1724.
66. Meyaard L, Schuitemaker H, Miedema F. T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today 1993;14:161-164.
67. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992;98: 279-285.
68. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
69. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993;14:335-338.
70. Clerici M, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-765.
71. Clerici M, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994;93:768-775.
72. Maggi E, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 1994;265:244-248.
73. Meyaard L, Otto S, Keet I, vanLier R, Miedema F. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood 1994;84:4262-4268.
74. Clerici M, Shearer G. A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
75. Vyakarnam A, Matear P, Martin S, Wagstaff M. Th1 cells specific for HIV-1 gag p24 are less efficient than Th0 cells in supporting HIV replication, and inhibit virus replication in Th0 cells. Immunology 1995;86:85-96.
76. Clerici M, et al. Type 1 cytokine production and low prevalence of viral isolation correlate with long term non-progression in HIV infection. AIDS Res Hum Retroviruses 1996;12: 1053-1061.
77. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987;238:800-802.
78. Clouse KA, et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989;142:431-438.
79. Rieckmann P, Poll G, Kehrl JH, Fauci AS. Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1. J Exp Med 1991;173:1-5.
80. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5:165-173.
81. Smithgall M, Wong JG, Critchett K, Haffar O. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 1996;156:2324-2330.
82. Bayard-McNeeley M, Doo H, He S, Hafner A, Johnson W, Ho J. Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro. Clin Diagn Lab Immunol 1996;3:547-553.
83. Kinter AL, Bende SM, Hardy EC, Jackson R, Fauci AS. Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995;92: 10985-10989.
84. Lucey D, et al. In vitro immunologic and virologie effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 1997;4:43-48.
85. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins A. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV infection: inhibition of mRNA expression. Nat Med 1997;3:659-664.
86. Maciaszek J, Parada N, Cruikshank W, Center D, Kornfeld H, Viglianti G. IL-16 represses HIV-1 promoter activity. J Immunol 1997;158:5-8.
87. Naif H, Li S, Ho-Shon M, Mathijs J, Williamson P, Cunningham A. The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. J Immunol 1997;158:501-511.
88. Weissman D, Poli G, Fauci AS. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:442-449.
89. Finnegan A, et al. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. J Immunol 1996;156:841-851.
90. Poli G, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990;172:151-158.
91. Poli G, Kinter AL, Fauci AS. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1994;91:108-112.
92. Schuitemaker H, et al. Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest 1992;89:1154-1160.
93. Poli G, Kinter AL, Justement JS, Bressler P, Kehrl JH, Fauci AS. Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med 1991;173:589-597.
94. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86:2336-2340.
95. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989;86:5974-5978.
96. Goletti D, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. J Immunol 1996;156:3501-3508.
97. Weissman D, Poli G, Fauci AS. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and interleukin 6 induction of virus. AIDS Res Hum Retroviruses 1994;10: 1199-1206.
98. Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995;154:2448-2459.
99. Schuitemaker H. IL4 and IL10 as potent inhibitors of HIV1 replication in macrophages in vitro: a role for cytokines in the in vivo virus host range? Res Immunol 1994;145:588-592.
100. Wallis RS, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized controlled trial. J Infect Dis 1996;174:727-733.
101. Clerici M, et al. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis 1997;175:1210-1215.
102. Kollmann TR, et al. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc Natl Acad Sci USA 1996;93:3126-3131.
103. Masood R, et al. IL-10 inhibits HIV-1 replication and is induced by tat. Biochem Biophys Res Commun 1994;202: 374-383.
104. Moore K, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann T. Interleukin-10. Annu Rev Immunol 1993;11:165-190.
105. Ho A, Moore K. Interleukin-10 and its receptor. Ther Immunol 1994;1:173-185.
106. Kovacs JA, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-1356.
107. Kinter A, Fauci AS. Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996;15:1-15.
108. Seder R, Grabstein K, Berzofsky J, McDyer J. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995;182:1067-1077.
109. Kanai T, Thomas E, Yasutomi Y, Letvin N. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol 1996;157:3681-3687.
110. Lin S, Roberts R, Ank B, Nguyen Q, Thomas E, Stiehm E. Human immunodeficiency virus (HIV) type-1 GP120-specific cell-mediated cytotoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: enhancement with interleukin-2(IL-2), IL-12, and IL-15. Clin Immunol Immunopathol 1997;82: 163-173.
111. Chehimi J, et al. IL-15 enhances immune functions during HIV infection. J Immunol 1997;158:5978-5987.
112. McKenzie A, Zurawski G. Interleukin-13: characterization and biologic properties. Cancer Treat Res 1995;80:367-378.
113. Montaner L, Gordon S. Th2-mediated HIV1 virostatic state: macrophage-specific regulation in vitro. Res Immunol 1994;145:583-587.
114. Gately M, Mulqueen M. Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases. Drugs 1996;52 (Suppl 2):18-25.
115. Trinchieri G, Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994;15:460-463.
116. Cruikshank W, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol 1996;157:5240-5248.
117. Theodore A, Center D, Nicoll J, Fine G, Kornfeld H, Cruikshank W. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 1996;157:1958-1964.
118. Yang OO, et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997;71:3120-3128.
119. Moriuchi H, Moriuchi M, Combadiere C, Murphy P, Fauci A. CD8+ T-cell-derived soluble factor(s), but not β-chemokines RANTES, MIP-1a, and MIP-1β, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA 1996;93: 15341-15345.
120. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ Lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
121. Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 1989;66:628-630.
122. Walker CM, Erickson AL, Hsueh FC, Levy JA. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol 1991;65:5921-5927.
123. Chen CH, Weinhold KJ, Bartlett JA, Bolognesi DP, Greenberg ML. CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses 1993;9: 1079-1086.
124. Copeland KF, McKay PJ, Rosenthal KL. Suppression of activation of the human immunodeficiency virus long terminal repeat by CD8+ T cells is not lentivirus specific. AIDS Res Hum Retroviruses 1995;11: 1321-1326.
125. Mackewicz C, Balckbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficiency virus replicaton by inhibiting viral transcription. Proc Natl Acad Sci USA 1995;92:2308-2312.
126. Mackewicz CE, Oretega H, Levy JA. Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol 1994;153:329-343.
127. Cocchi F, DeVico A, Garzino-Demo A, Arya S, Gallo R, Lusso P. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
128. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new CC-chemokine receptor gene, CC-CKR5. Biochemistry 1996;35:3362-3367.
129. Combadiere C, Ahuja S, Tiffany H, Murphy P. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 (alpha), MIP-1(beta), and RANTES. J Leukoc Biol 1996;60:147-152.
130. Raport C, Gosling J, Schweickart V, Gray P, Charo I. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996;271:17161-17166.
131. Oravecz T, Pall M, Norcross M. β-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol 1996;157:1329-1332.
132. Simmons G, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-8360.
133. Zhang L, Huang Y, He T, Cao Y, Ho D. HIV-1 subtype and second receptor use. Nature 1996;383:768.
134. He J, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997;385:645-649.
135. Schall T. Biology of the RANTES/sis cytokine family. Cytokine 1991;3:165-183.
136. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
137. Nelson P, Kim H, Manning W, Goralski T, Krensky A. Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 1993;151:2601-2612.
138. Rathanaswami P, Hachicha M, Sadick M, Schall T, McColl S. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993;268:5834-5839.
139. Schall T, Bacon K. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994;6:865-873.
140. Bleul C, Wu L, Hoxie J, Springer T, MacKay C. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
141. Zhu T, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261:1179-1181.
142. Zhang LQ, Mackenzie P, Cleland A, Holmes EC, Leigh-Brown AJ, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993;67:3345-3356.
143. Unutmaz D, Littman D. Expression pattern of HIV-1 coreceptors on T cells: implications for viral transmission and lymphocyte homing. Proc Natl Acad Sci USA 1997;94:1615-1618.
144. Simmons G, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
145. Kinter AL, et al. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci USA 1996;93: 14076-14081.
146. Jansson M, et al. Sensitivity to inhibition by β-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996;93: 15382-15387.
147. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
148. York-Higgins D, Cheng-Mayer C, Bauer D, Levy JA, Dina D. Human immunodeficiency virus type 1 cellular host range, replication, cytopathicity are linked to the envelope region of the viral genome. J Virol 1990;64:4016-4020.
149. deJong JJ, et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-765.
150. Kuiken CL, deJong JJ, Baan E, Keulen W, Tersmette M, Goudsmit J. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992;66:4622-4627.
151. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
152. Takeuchi Y, Akutsu M, Murayama K, Shimuzu N, Hoshino H. Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol 1991;65:1710-1718.
153. Cheng-Mayer C, Shioda T, Levy JA. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by a very few amino acid changes in tat and gp120. J Virol 1991;65:6931-6941.
154. Fouchier RA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
155. Bhattacharyya D, Brooks BR, Callahan L. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. AIDS Res Hum Retroviruses 1996;12:83-90.
156. Cocchi F, DeVico A, Garzino-Demo A, Cara A, Gallo R, Lusso P. The V3 domain of HIV-1 envelope glycoprotein gp120 is critical for chemokine-mediated blockade of infection. Nat Med 1996;2:1244-1247.
157. Koot M, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
158. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication. Nature 1996;382:767.
159. Michael N, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-340.
160. Mellors JW, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579.
161. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
162. Bukrinsky M, Stanwick T, Dempsey M, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
163. Finberg R, et al. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991;252:1703-1705.
164. Bell K, Ramilo O, Vitetta E. Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Natl Acad Sci USA 1993;90:1411-1415.
165. Quinn T, et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. J Am Med Assoc 1987;257:2617-2621.
166. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995;16:187-191.
167. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
168. Wallis R, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis 1993;167:43-48.
169. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151: 129-135.
170. Goletti D, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996;157:1271-1278.
171. Israel-Biet D, Cadranel J, Even P. Human immunodeficiency virus production by alveolar lymphocytes is increased during Pneumocystis carinii pneumonia. Am Rev Respir Dis 1993;148:1308-1312.
172. Orenstein J, Fox C, Wahl S. Macrophages as a source of HIV during opportunistic infections. Science 1997;276:1857-1861.
173. Staprans S, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-1737.
174. Stanley S, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230.
175. Lifson AR, et al. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis 1991;163:959-965.
176. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993;7:1159-1166.
177. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994;8:1123-1128.
178. Keet IP, et al. Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis 1994;169:1236-1243.
179. Munoz A, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:496-505.
180. Pantaleo G, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-216.
181. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologie and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.
182. Vicenzi E, et al. Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood 1997;89:191-200.
183. Balotta C, et al. Comparable biological and molecular determinants in HIV type 1-infected long-term nonprogressors and recently infected individuals. AIDS Res Hum Retroviruses 1997;13: 337-341.
184. Schrager L, Young J, Fowler M, Mathieson B, Vermund S. Long-term survivors of HIV-1 infection: definitions and research challenges. AIDS 1994;8 (Suppl 1):S95-108.
185. Learmont J, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992;340:863-867.
186. Deacon NJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
187. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332:228-232.
188. Iversen AKN, et al. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol 1995;69:5743-5753.
189. Michael NL, et al. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol 1995;69:4228-4236.
190. Michael NL, Chang G, D'arcy LA, Tseng CJ, Birx DL, Sheppard HW. Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. J Virol 1995;69:6758-6769.
191. Huang Y, Zhang L, Ho DD. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1995;69:93-100.
192. Huang Y, Zhang L, Ho D. Biological characterization of nef in long term survivors of human immunodeficiency virus type 1 infection. J Virol 1995;69:8142-8146.
193. Kaslow RA, et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. Lancet 1990;335:927-930.
194. Klein MR, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam Cohort of Homosexual Men. J Infect Dis 1994;169:1244-1249.
195. Keet IP, Klein MR, Just JJ, Kaslow RA. The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack. AIDS 1996;10(Suppl A):S59-S67.
196. Kaslow RA, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-411.
197. Eales L-J, et al. Association of different allelic forms of group specific component with susceptibility to and clinical manifestation of human immunodeficiency virus infection. Lancet 1987;i: 999-1002.
198. Garred P, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997;349:236-240.
199. Khoo SH, et al. The TNF c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 1997;11:423-428.
200. Samson M, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
201. Liu R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
202. Zimmerman P, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial backgrounds and quantified risks. Mol Med 1997;3:23-36.
203. Dean M, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862.
204. Huang Y, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
205. Biti R, French R, Young J, Bennetts B, Stewart G. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-253.
206. O'Brien T, et al. HIV-1 infection in a man homozygous for CCR5Δ32. Lancet 1997;349:1219.
207. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5Δ32. Lancet 1997;349:1219-1220.
208. Wu L, et al. CCR5 levels and expression pattern correlate wtih infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-1692.
209. Cohen O, et al. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long term non-progressors. J Clin Invest 1997;100:1581-1589.
210. Eugen-Olsen J, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS free survival and slower CD4 T cell fall in a cohort of HIV seropositive individuals. AIDS 1997;11:305-310.
211. Pantaleo G, Vaccarezza M, Graziosi C, Cohen OJ, Fauci AS. Antiviral immunity in HIV-1 infected long-term non-progressors (LTNPs). Semin Virol 1996;7:131-138.
212. Gotch F, Gallimore A, McMichael A. Cytotoxic T cells - protection from disease progression - protection from infection. Immunol Lett 1996;51:125-128.
213. Jassoy C, Walker B. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin Immunopathol 1997;18: 341-354.
214. Harrer T, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996;156:2616-2623.
215. Harrer T, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12: 585-592.
216. Rinaldo C, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69:5838-5842.
217. Klein MR, et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
218. Riviere Y, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995;11: 903-907.
219. Goulder PJ, et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12: 1691-1698.
220. Pantaleo G, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997;94:254-258.
221. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
222. Pantaleo G, et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997 (In press).
223. Zinkernagel RM, Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 1994;15:262-268.
224. Koup RA, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
225. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
226. Goulder PJR, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
227. Phillips RE, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:433-434.
228. Koenig S, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995;1:330-336.
229. Borrow P, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
230. Klenerman P, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 1994;369:403-407.
231. Meier U-C, et al. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 1995;270:1360-1362.
232. Itescu S, Rose S, Dwyer E, Winchester R. Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression. Proc Natl Acad Sci USA 1994;91: 11472-11476.
233. Kalams SA, et al. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clone reveals a limited TCR repertoire. J Exp Med 1994;179:1261-1271.
234. Kalams SA, et al. T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J Exp Med 1996;183:1669-1679.
235. Wilson CC, et al. Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. J Virol 1997;71:1256-1264.
236. Wolinsky SM, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-542.
237. Haas G, et al. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol 1996;157:4212-4221.
238. Nowak MA, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
239. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-1466.
240. Scala E, et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997;158:4485-4492.
241. McKenzie S, Dallalio G, North M, Frame P, Means R. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996;10:29-33.
242. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, DePaoli P. Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients. AIDS 1996;10:1431-1432.
243. Clerici M, et al. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 1996;10:1432-1433.
244. Chen Y, Gupta P. CD8+ T-cell-mediated suppression of HIV-1 infection may not be due to chemokines RANTES, MIP-1α, and MIP-1β. AIDS 1996;10:1434-1435.
245. Blazevic V, Heino M, Ranki A, Jussila T, Krohn K. RANTES, MIP, and interleukin-16 in HIV infection. AIDS 1996;10:1435-1436.
246. Furci L, et al. Antigen-driven C-C Chemokine-mediated HIV-1 Suppression by CD4(+) T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR- 5 Allele. J Exp Med 1997;186:455-460.
247. Schall T, Bacon K, Toy K, Goeddel D. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-671.
248. Amara A, et al. HIV co-receptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997;186:139-146.
249. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature 1995;378:563.
250. Zwart G, et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 1994;201:285-293.
251. Wong MT, et al. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-uninfected subjects. J Infect Dis 1993;168:1523-1527.
252. Hogervorst E, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995;171:811-821.
253. Montefiori DC, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173:60-67.
254. Sei Y, Tsang PH, Roboz JP, Sarin PS, Wallace JI, Bekesi JG. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study. J Clin Immunol 1988;8:464-472.
255. Tsang ML, et al. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994;170:1141-1147.
256. Pilgrim A, et al. Neutralizing antibody responses at various stages of infection with human immunodeficiency virus type 1. J Infect Dis 1997 (In press).
257. Arendrup M, Nielsen C, Hansen J-ES, Pedersen C, Mathiesen L, Nielsen JO. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992;5: 303-307.
258. Ioachim HL, Lerner CW, Tapper ML. The lymphoid lesions associated with the acquired immunodeficiency syndrome. Am J Surg Pathol 1983;7:543-553.
259. Fernandez R, Mouradian J, Metroka C, Davies J. The prognostic value of histopathology in persistent generalized lymphadenopathy in homosexual men. N Engl J Med 1983;309:185-186.
260. Janossy G, et al. An immunohistological approach to persistent lymphadenopathy and its relevance to AIDS. Clin Exp Immunol 1985;59:257-266.
261. Biberfeld P, Chayt K, Marselle L, Biberfeld G, Gallo R, Harper M. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol 1986;125:436-442.
262. Racz P, Tenner-Racz K, Kahl C, Feller AC, Kern P, Dietrich M. Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes. Prog Allergy 1986;37:81-181.
263. Pallesen G, Gerstoft J, Mathiesen L. Stages in LAV/HTLV-III lymphadenitis: I. Histological and immunohistological classification. Scand J Immunol 1987;25:83-91.
264. Turner R, Levine A, Gill P, Parker J, Meyer P. Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. Am J Surg Pathol 1987;11:625-632.